Evergreen Capital Management LLC Increases Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Evergreen Capital Management LLC grew its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 19.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 298,317 shares of the biopharmaceutical company’s stock after acquiring an additional 49,284 shares during the period. Evergreen Capital Management LLC’s holdings in Royalty Pharma were worth $7,867,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in RPRX. Swedbank AB purchased a new position in shares of Royalty Pharma in the first quarter valued at about $251,461,000. New South Capital Management Inc. purchased a new position in shares of Royalty Pharma in the first quarter valued at about $44,384,000. ADAR1 Capital Management LLC purchased a new position in shares of Royalty Pharma in the fourth quarter valued at about $37,130,000. Patient Capital Management LLC purchased a new position in shares of Royalty Pharma in the fourth quarter valued at about $35,247,000. Finally, Homestead Advisers Corp lifted its position in shares of Royalty Pharma by 40.7% in the first quarter. Homestead Advisers Corp now owns 1,892,540 shares of the biopharmaceutical company’s stock valued at $57,502,000 after acquiring an additional 547,000 shares in the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on RPRX shares. Morgan Stanley boosted their price objective on Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, July 11th. The Goldman Sachs Group boosted their target price on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. Finally, UBS Group downgraded Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 target price on the stock. in a research report on Monday, June 3rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Royalty Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Royalty Pharma Trading Down 1.6 %

Shares of NASDAQ RPRX opened at $27.54 on Monday. The business’s 50 day moving average is $28.00 and its two-hundred day moving average is $27.98. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.35 and a quick ratio of 9.35. Royalty Pharma plc has a 1-year low of $25.20 and a 1-year high of $31.66. The stock has a market capitalization of $16.45 billion, a P/E ratio of 20.55, a PEG ratio of 4.17 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The company had revenue of $537.00 million for the quarter, compared to analysts’ expectations of $600.83 million. During the same period in the previous year, the firm posted $0.85 earnings per share. As a group, research analysts expect that Royalty Pharma plc will post 4.04 EPS for the current year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 13th. Shareholders of record on Friday, August 16th were paid a dividend of $0.21 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $0.84 annualized dividend and a yield of 3.05%. Royalty Pharma’s payout ratio is currently 62.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.